News Release: Moderna: Clinical Trial Data Demonstrate Strong Response Against Eris and FL.1.5.1 Variants


In the upcoming fall, vaccination may be necessary for Eris (EG.5) and FL.1.5.1, as they are believed to be the variants of concern.

Moderna  (Adobe Stock, unknown)

Moderna vaccination

(Adobe Stock, unknown)

Moderna has reported encouraging news regarding its updated COVID-19 vaccine ahead of the upcoming fall and winter season and the beginning of the school year. According to Moderna’s latest announcement, the vaccine has shown a notable increase in neutralizing antibodies against the Eris (EG.5) and FL.1.5.1 variants. This is a significant development, following the earlier news that the vaccine, designed for autumn 2023, had already demonstrated strong human immune responses against the key circulating XBB strains at the FDA VRBPAC meeting in June 2023.

“These new results, which show that our updated COVID-19 vaccine generates a robust immune response against the rapidly spreading EG.5 and FL 1.5.1 strains and reflects our updated vaccine’s ability to address emerging COVID-19 threats,” said Stephen Hoge, MD, president of Moderna, said in the press release. “Moderna is committed to leveraging our mRNA technology to provide health security around the world.”

As of August 5, EG.5 has become the predominant COVID-19 variant in the US, with 17.3% of new cases, reported the CDC. The WHO has also identified EG.5 in over 50 countries as of August 8th.

With the definition of COVID-19 infection unclear and the numbers of COVID-19 cases rising, the announcement is positive news in the ongoing fight against the disease.

“Moderna has submitted its updated COVID-19 vaccine to the US Food and Drug Administration, the European Medicines Agency (EMA), and other regulators around the world. Pending authorization, it will be ready for fall vaccination with sufficient global supply,” according to the press release.

The autumn may be of concern, with hospitalizations up 12.5% and deaths increased by 10%, according to the CDC. Wastewater surveillance indicates a rise as well. To adequately safeguard against the potential threat, multiple forms of protection may be necessary, according to experts.

Recent Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Related Content